{"gene":"HPD","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":2019,"finding":"HPD protein stability is regulated by a TTC36-STK33-PELI1 signaling axis: TTC36 binds HPD and blocks STK33 from phosphorylating HPD at T382; T382 phosphorylation recruits the FHA-domain E3 ligase PELI1, which polyubiquitylates HPD and targets it for proteasomal degradation. TTC36 deficiency in mice reduces hepatic HPD, causing tyrosinemia and hippocampal neuronal damage.","method":"Co-immunoprecipitation, phosphorylation assays, ubiquitylation assays, Ttc36-knockout mouse model with biochemical and behavioral phenotyping","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP plus phosphorylation/ubiquitylation assays plus in vivo KO mouse phenotype, multiple orthogonal methods in a single rigorous study","pmids":["31537781"],"is_preprint":false},{"year":2021,"finding":"Loss of HPD enzymatic activity in liver cells reduces ketone body production, which activates the AMPK/mTOR/p70S6K pathway and mTOR-dependent glutaminase (GLS) activation, shifting cellular metabolism toward glutamine anaplerosis and TCA cycle replenishment, thereby promoting tumorigenic and proliferative phenotypes.","method":"HPD silencing (siRNA/shRNA) in liver cancer cell lines, metabolomics profiling, isotope tracing (13C-glutamine), AMPK/mTOR pathway inhibitor experiments","journal":"Cell Reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — isotope tracing plus metabolomics plus pathway inhibitor epistasis in a single study with multiple orthogonal methods","pmids":["34433044"],"is_preprint":false},{"year":2025,"finding":"Beyond its canonical enzymatic role, HPD functions as an RNA-binding protein (RBP) that binds the RRACH motif of target mRNAs through two dsRNA-binding domains (RBDs), enhancing global mRNA translation. Specifically, HPD binding promotes translation of glycolytic enzyme mRNAs TPI and ENO1, driving glycolysis, tumor growth, and drug resistance in ovarian cancer cells.","method":"RNA-binding protein assays, identification of RBDs by domain mapping, mRNA translation assays, glycolysis flux measurements, RBD-domain disruption experiments, tumor growth and drug response assays","journal":"Advanced Science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct RNA-binding and functional translation assays, single lab, multiple orthogonal methods; preprint/recent publication, not yet independently replicated","pmids":["40491422"],"is_preprint":false},{"year":2000,"finding":"HPD (4-hydroxyphenylpyruvate dioxygenase) catalyzes the second step in tyrosine catabolism; genetic deficiency (loss-of-function mutations including missense and nonsense mutations) causes accumulation of tyrosine and phenolic metabolites, resulting in tyrosinemia type III with neurological symptoms.","method":"Mutation identification in HPD gene by sequencing in patients with biochemically confirmed enzyme deficiency; genotype-phenotype correlation","journal":"Human Genetics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — sequencing-based mutation identification in multiple unrelated families with confirmed enzyme deficiency; establishes catalytic function by loss-of-function but no in vitro reconstitution","pmids":["10942115"],"is_preprint":false},{"year":1995,"finding":"A nonsense mutation in exon 7 of the mouse Hpd gene causes partial exon skipping, generating a truncated non-functional enzyme, leading to reduced 4-hydroxyphenylpyruvate dioxygenase activity and hypertyrosinemia in mouse strain III; this strain is a model for human tyrosinemia type 3.","method":"Genomic sequencing, RT-PCR to detect exon skipping, enzymatic activity assays in liver tissue","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — combined sequencing, mRNA analysis, and enzymatic activity measurement; single study but multiple orthogonal methods","pmids":["7774914"],"is_preprint":false},{"year":2000,"finding":"In Fah-/- Hpd-/- double-mutant mice, the absence of HPD activity prevents accumulation of homogentisate-derived toxic metabolites (including succinylacetone) and protects against liver and renal disease. When homogentisate is exogenously administered to Fah-/- Hpd-/- mice, rapid apoptosis of proximal renal tubular cells occurs via caspase-dependent mechanisms, and renal Fanconi syndrome develops; apoptosis was blocked by caspase inhibitor YVAD but renal dysfunction was not, indicating these operate through separate pathways.","method":"Double-mutant mouse model (Fah-/- Hpd-/-), homogentisate administration, caspase inhibitor pretreatment (YVAD), urine metabolite analysis, histopathology","journal":"Journal of the American Society of Nephrology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic double-KO model with pharmacological intervention (caspase inhibitor), in vivo metabolite tracing, and histopathology; multiple orthogonal methods establishing pathway position","pmids":["10665936"],"is_preprint":false},{"year":1994,"finding":"The human HPD gene is over 30 kb long, split into 14 exons, and expressed predominantly in liver. Analysis of the 5' flanking region identified hepatocyte-specific and liver-enriched transcription factor binding sites consistent with regulated hepatic expression.","method":"Genomic library screening, restriction mapping, exon-boundary sequencing, Northern blot analysis of tissue expression, 5'-flanking sequence analysis","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — genomic structure determination with Northern blot confirmation of liver-specific expression; single study but direct experimental characterization of gene structure and expression","pmids":["7851880"],"is_preprint":false},{"year":1997,"finding":"The human HPD gene spans ~21 kb with 14 exons and 13 introns; the transcription start site is 35 nt upstream of the translational start. The 5'-flanking region contains CRE, AP-2, and Sp1 regulatory elements; transient transfection with CAT reporter constructs indicated that cAMP may regulate HPD transcription. Highest expression is in liver by Northern blot.","method":"Genomic library screening, PCR, DNA sequencing, Northern blot, transient transfection with CAT reporter constructs","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct characterization of promoter elements with functional reporter assay; single lab, liver-specific expression confirmed by Northern blot","pmids":["9325050"],"is_preprint":false},{"year":2021,"finding":"CRISPR-Cas9-mediated biallelic disruption of HPD in FAH-deficient pigs redirects tyrosine catabolism upstream of the pathogenic pathway, protecting against fumarylacetoacetate hydrolase deficiency-induced lethal liver injury; HPD ablation also ameliorated oxidative stress, inflammatory responses, and restored liver metabolic gene expression profiles.","method":"CRISPR-Cas9 cytoplasmic microinjection in FAH-mutant pig embryos, F1 generation characterization, liver histopathology, gene expression profiling, oxidative stress assays","journal":"Molecular Therapy: Methods & Clinical Development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — large-animal genetic epistasis model demonstrating HPD's pathway position upstream of pathogenic metabolites; single study with multiple phenotypic readouts","pmids":["33997102"],"is_preprint":false},{"year":2024,"finding":"Computational modeling and in silico evolutionary analysis of human 4-HPPD revealed that the C-terminal tail acts as a gating mechanism for the active site, with two novel residues identified as key regulators of C-terminal tail conformational change; a full-length 3D structural model of human 4-HPPD was proposed.","method":"Bioinformatics/molecular dynamics simulations, evolutionary analysis, homology modeling; no experimental in vitro or structural validation","journal":"Biomedicines","confidence":"Low","confidence_rationale":"Tier 4 / Weak — computational prediction only; no experimental structural or functional validation reported in the abstract","pmids":["38927403"],"is_preprint":false}],"current_model":"HPD (4-hydroxyphenylpyruvate dioxygenase) catalyzes the second step of tyrosine catabolism (conversion of 4-hydroxyphenylpyruvate to homogentisate) primarily in liver; its stability is regulated by the TTC36-STK33-PELI1 axis (TTC36 blocks STK33-mediated T382 phosphorylation that otherwise recruits PELI1 for polyubiquitylation and degradation); loss of HPD reduces ketone bodies, activating mTOR/GLS-dependent glutamine anaplerosis; and unexpectedly HPD also functions as an RNA-binding protein that promotes translation of glycolytic enzyme mRNAs (TPI, ENO1) through dsRNA-binding domains."},"narrative":{"mechanistic_narrative":"HPD (4-hydroxyphenylpyruvate dioxygenase) catalyzes the second step of tyrosine catabolism, converting 4-hydroxyphenylpyruvate to homogentisate, and is expressed predominantly in liver under hepatocyte-specific transcriptional control [PMID:10942115, PMID:7851880]. Loss-of-function mutations abolish this activity and cause accumulation of tyrosine and phenolic metabolites, producing tyrosinemia type III with neurological features in humans and a parallel hypertyrosinemia phenotype in mouse [PMID:10942115, PMID:7774914]. Because HPD acts upstream of the toxic homogentisate-derived metabolites (including succinylacetone) generated in fumarylacetoacetate hydrolase deficiency, genetic ablation of HPD in Fah-deficient mice and pigs redirects flux away from the pathogenic branch and protects against lethal liver and renal injury; exogenous homogentisate restores caspase-dependent apoptosis of proximal renal tubular cells, placing HPD precisely at this metabolic branch point [PMID:10665936, PMID:33997102]. HPD protein abundance is set post-translationally by a TTC36-STK33-PELI1 axis: STK33 phosphorylates HPD at T382 to recruit the FHA-domain E3 ligase PELI1 for polyubiquitylation and proteasomal degradation, while TTC36 binding blocks this phosphorylation, and TTC36 loss in mice depletes hepatic HPD, causing tyrosinemia and hippocampal damage [PMID:31537781]. Beyond catabolism, loss of HPD enzymatic activity lowers ketone body production and activates AMPK/mTOR/p70S6K signaling and mTOR-dependent glutaminase to drive glutamine anaplerosis and proliferative phenotypes [PMID:34433044]. HPD additionally moonlights as an RNA-binding protein that recognizes the RRACH motif through two dsRNA-binding domains and enhances translation of glycolytic enzyme mRNAs TPI and ENO1, promoting glycolysis, tumor growth, and drug resistance [PMID:40491422].","teleology":[{"year":1994,"claim":"Establishing where HPD is expressed and how it is transcriptionally controlled was needed to anchor its physiological role; defining the gene's structure and liver-enriched expression located its function in hepatic tyrosine metabolism.","evidence":"Genomic library screening, exon-boundary sequencing, Northern blot tissue profiling, and 5'-flanking analysis","pmids":["7851880","9325050"],"confidence":"Medium","gaps":["Promoter element function tested only by reporter assay, not in vivo","Does not address extra-hepatic expression or non-catalytic functions"]},{"year":1995,"claim":"A causal link between Hpd disruption and disease was established in vivo when a nonsense mutation causing exon skipping produced a truncated enzyme and hypertyrosinemia, defining a tyrosinemia type III model.","evidence":"Genomic sequencing, RT-PCR exon-skipping analysis, and liver enzymatic activity assays in mouse strain III","pmids":["7774914"],"confidence":"Medium","gaps":["No in vitro reconstitution of the truncated enzyme","Mechanism of neurological consequences not addressed"]},{"year":2000,"claim":"Whether human HPD mutations are disease-causing was confirmed by identifying loss-of-function mutations in patients with biochemically confirmed enzyme deficiency, defining HPD as the catalytic basis of tyrosinemia type III.","evidence":"Mutation sequencing and genotype-phenotype correlation in unrelated families with confirmed enzyme deficiency","pmids":["10942115"],"confidence":"Medium","gaps":["No in vitro enzymatic reconstitution of mutant proteins","Structure-function basis of individual mutations not resolved"]},{"year":2000,"claim":"The precise pathway position of HPD relative to downstream toxic metabolites was resolved using a Fah/Hpd double-knockout, showing HPD acts upstream of homogentisate-derived succinylacetone and that its ablation is protective.","evidence":"Fah-/- Hpd-/- mouse model, exogenous homogentisate administration, caspase-inhibitor (YVAD) intervention, urine metabolite analysis, and histopathology","pmids":["10665936"],"confidence":"High","gaps":["Mechanism linking homogentisate to caspase-independent renal dysfunction unresolved","Does not address HPD regulation"]},{"year":2019,"claim":"How HPD protein levels are controlled post-translationally was unknown; the TTC36-STK33-PELI1 axis was defined as a phosphorylation- and ubiquitylation-dependent stability switch governing hepatic HPD abundance.","evidence":"Reciprocal Co-IP, T382 phosphorylation and ubiquitylation assays, and a Ttc36-knockout mouse with biochemical and behavioral phenotyping","pmids":["31537781"],"confidence":"High","gaps":["Stimuli that engage STK33-mediated HPD phosphorylation not defined","Whether this axis operates outside liver unknown"]},{"year":2021,"claim":"The metabolic consequences of losing HPD enzymatic activity were defined: reduced ketone bodies activate AMPK/mTOR signaling and glutaminase-driven glutamine anaplerosis, reprogramming metabolism toward proliferation.","evidence":"HPD silencing in liver cancer cells, metabolomics, 13C-glutamine isotope tracing, and AMPK/mTOR inhibitor epistasis","pmids":["34433044"],"confidence":"High","gaps":["Whether this signaling cascade operates in normal hepatocytes vs cancer cells unclear","Direct sensor linking ketone levels to AMPK not identified"]},{"year":2021,"claim":"HPD's epistatic position was confirmed in a large-animal model when biallelic CRISPR disruption in FAH-deficient pigs rerouted tyrosine catabolism upstream of pathogenic metabolites and protected against lethal liver injury.","evidence":"CRISPR-Cas9 embryo microinjection in FAH-mutant pigs, liver histopathology, expression profiling, and oxidative stress assays","pmids":["33997102"],"confidence":"Medium","gaps":["Long-term metabolic consequences of HPD ablation in pigs not assessed","Single study"]},{"year":2025,"claim":"A non-catalytic moonlighting function was uncovered: HPD binds RRACH-motif mRNAs through two dsRNA-binding domains and enhances translation of glycolytic enzyme transcripts TPI and ENO1, linking it to glycolysis and tumor phenotypes.","evidence":"RNA-binding assays, domain mapping of RBDs, translation and glycolysis flux measurements, and RBD-disruption tumor/drug-response experiments","pmids":["40491422"],"confidence":"Medium","gaps":["Single lab, not independently replicated","Relationship between RNA-binding and catalytic functions of HPD undefined","Structural basis of RRACH recognition unresolved"]},{"year":2024,"claim":"A structural rationale for HPD active-site regulation was proposed in silico, identifying a C-terminal gating tail and key residues governing its conformational change.","evidence":"Molecular dynamics simulations, evolutionary analysis, and homology modeling without experimental validation","pmids":["38927403"],"confidence":"Low","gaps":["Purely computational; no experimental structural or functional validation","Predicted gating residues not tested by mutagenesis"]},{"year":null,"claim":"How HPD's enzymatic, stability-control, and RNA-binding functions are integrated within a single protein and coordinated across tissues remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No experimental structure of full-length human HPD or its RNA-bound state","Unknown whether RNA-binding competes with or is independent of catalysis","Physiological triggers of the TTC36-STK33-PELI1 axis undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[3,4,5]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[2]}],"localization":[],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[3,5]}],"complexes":[],"partners":["TTC36","STK33","PELI1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P32754","full_name":"4-hydroxyphenylpyruvate dioxygenase","aliases":["4-hydroxyphenylpyruvic acid oxidase","4HPPD","HPD","HPPDase"],"length_aa":393,"mass_kda":45.0,"function":"Catalyzes the conversion of 4-hydroxyphenylpyruvic acid to homogentisic acid, one of the steps in tyrosine catabolism","subcellular_location":"Cytoplasm; Endoplasmic reticulum membrane; Golgi apparatus membrane","url":"https://www.uniprot.org/uniprotkb/P32754/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HPD","classification":"Not Classified","n_dependent_lines":12,"n_total_lines":1208,"dependency_fraction":0.009933774834437087},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/HPD","total_profiled":1310},"omim":[{"mim_id":"618994","title":"4-@HYDROXYPHENYLPYRUVATE DIOXYGENASE-LIKE; HPDL","url":"https://www.omim.org/entry/618994"},{"mim_id":"617048","title":"DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 21; DNAJC21","url":"https://www.omim.org/entry/617048"},{"mim_id":"614334","title":"DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 13; DNAJC13","url":"https://www.omim.org/entry/614334"},{"mim_id":"611341","title":"DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 11; DNAJB11","url":"https://www.omim.org/entry/611341"},{"mim_id":"609695","title":"4-@HYDROXYPHENYLPYRUVATE DIOXYGENASE; HPD","url":"https://www.omim.org/entry/609695"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Nuclear speckles","reliability":"Uncertain"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":2365.4}],"url":"https://www.proteinatlas.org/search/HPD"},"hgnc":{"alias_symbol":["4-HPPD","4HPPD","GLOD3","HPPD"],"prev_symbol":["PPD"]},"alphafold":{"accession":"P32754","domains":[{"cath_id":"3.10.180.10","chopping":"11-173","consensus_level":"medium","plddt":97.5763,"start":11,"end":173},{"cath_id":"3.10.180.10","chopping":"179-379","consensus_level":"medium","plddt":93.6456,"start":179,"end":379}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P32754","model_url":"https://alphafold.ebi.ac.uk/files/AF-P32754-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P32754-F1-predicted_aligned_error_v6.png","plddt_mean":95.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HPD","jax_strain_url":"https://www.jax.org/strain/search?query=HPD"},"sequence":{"accession":"P32754","fasta_url":"https://rest.uniprot.org/uniprotkb/P32754.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P32754/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P32754"}},"corpus_meta":[{"pmid":"8621599","id":"PMC_8621599","title":"A conserved HPD sequence of the J-domain is necessary for YDJ1 stimulation of Hsp70 ATPase activity at a site distinct from substrate binding.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8621599","citation_count":226,"is_preprint":false},{"pmid":"22242141","id":"PMC_22242141","title":"The c4h, tat, hppr and hppd genes prompted engineering of rosmarinic acid biosynthetic pathway in Salvia miltiorrhiza hairy root cultures.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22242141","citation_count":101,"is_preprint":false},{"pmid":"20093016","id":"PMC_20093016","title":"Effect of bioaugmentation by Paracoccus sp. strain HPD-2 on the soil microbial community and removal of polycyclic aromatic hydrocarbons from an aged contaminated soil.","date":"2010","source":"Bioresource technology","url":"https://pubmed.ncbi.nlm.nih.gov/20093016","citation_count":93,"is_preprint":false},{"pmid":"9445202","id":"PMC_9445202","title":"Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model.","date":"1998","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9445202","citation_count":60,"is_preprint":false},{"pmid":"7073939","id":"PMC_7073939","title":"Photodynamic action and chromosomal damage: a comparison of haematoporphyrin derivative (HpD) and light with X-irradiation.","date":"1982","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/7073939","citation_count":58,"is_preprint":false},{"pmid":"23251397","id":"PMC_23251397","title":"Structures of the human poly (ADP-ribose) glycohydrolase catalytic domain confirm catalytic mechanism and explain inhibition by ADP-HPD derivatives.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23251397","citation_count":54,"is_preprint":false},{"pmid":"34657203","id":"PMC_34657203","title":"A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation.","date":"2021","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/34657203","citation_count":50,"is_preprint":false},{"pmid":"28443128","id":"PMC_28443128","title":"Physiological and Molecular Characterization of Hydroxyphenylpyruvate Dioxygenase (HPPD)-inhibitor Resistance in Palmer Amaranth (Amaranthus palmeri S.Wats.).","date":"2017","source":"Frontiers in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/28443128","citation_count":47,"is_preprint":false},{"pmid":"8933363","id":"PMC_8933363","title":"'Hamster-like' cycles in testicular size in the absence of gonadotrophin secretion in HPD rams exposed to long-term changes in photoperiod and treatment with melatonin.","date":"1996","source":"Journal of neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/8933363","citation_count":47,"is_preprint":false},{"pmid":"10942115","id":"PMC_10942115","title":"Mutations in the 4-hydroxyphenylpyruvate dioxygenase gene (HPD) in patients with tyrosinemia type III.","date":"2000","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10942115","citation_count":44,"is_preprint":false},{"pmid":"33039827","id":"PMC_33039827","title":"Cobalt (II) complex as a fluorescent sensing platform for the selective and sensitive detection of triketone HPPD inhibitors.","date":"2020","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/33039827","citation_count":44,"is_preprint":false},{"pmid":"31854080","id":"PMC_31854080","title":"Evolution of resistance to HPPD-inhibiting herbicides in a wild radish population via enhanced herbicide metabolism.","date":"2020","source":"Pest management science","url":"https://pubmed.ncbi.nlm.nih.gov/31854080","citation_count":43,"is_preprint":false},{"pmid":"29105299","id":"PMC_29105299","title":"Tembotrione detoxification in 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor-resistant Palmer amaranth (Amaranthus palmeri S. Wats.).","date":"2018","source":"Pest management science","url":"https://pubmed.ncbi.nlm.nih.gov/29105299","citation_count":38,"is_preprint":false},{"pmid":"19811689","id":"PMC_19811689","title":"HPD: an online integrated human pathway database enabling systems biology studies.","date":"2009","source":"BMC bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/19811689","citation_count":38,"is_preprint":false},{"pmid":"7822043","id":"PMC_7822043","title":"The gene encoding protein D (hpd) is highly conserved among Haemophilus influenzae type b and nontypeable strains.","date":"1995","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/7822043","citation_count":35,"is_preprint":false},{"pmid":"6474583","id":"PMC_6474583","title":"Laser phototherapy following HpD administration in superficial neoplastic lesions.","date":"1984","source":"Tumori","url":"https://pubmed.ncbi.nlm.nih.gov/6474583","citation_count":35,"is_preprint":false},{"pmid":"34433044","id":"PMC_34433044","title":"Loss of tyrosine catabolic enzyme HPD promotes glutamine anaplerosis through mTOR signaling in liver cancer.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34433044","citation_count":33,"is_preprint":false},{"pmid":"10665936","id":"PMC_10665936","title":"A mouse model of renal tubular injury of tyrosinemia type 1: development of de Toni Fanconi syndrome and apoptosis of renal tubular cells in Fah/Hpd double mutant mice.","date":"2000","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/10665936","citation_count":33,"is_preprint":false},{"pmid":"7537236","id":"PMC_7537236","title":"The role of angiogenesis in the tumor growth of Syrian hamster pancreatic cancer cell line HPD-NR.","date":"1995","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/7537236","citation_count":33,"is_preprint":false},{"pmid":"8104899","id":"PMC_8104899","title":"Limited diversity of the protein D gene (hpd) among encapsulated and nonencapsulated Haemophilus influenzae strains.","date":"1993","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/8104899","citation_count":32,"is_preprint":false},{"pmid":"19028100","id":"PMC_19028100","title":"Design, synthesis and herbicidal activity of new iron chelating motifs for HPPD-inhibitors.","date":"2008","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19028100","citation_count":32,"is_preprint":false},{"pmid":"30081124","id":"PMC_30081124","title":"Isolation of pyomelanin from bacteria and evidences showing its synthesis by 4-hydroxyphenylpyruvate dioxygenase enzyme encoded by hppD gene.","date":"2018","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/30081124","citation_count":31,"is_preprint":false},{"pmid":"34719096","id":"PMC_34719096","title":"Design, synthesis and biological activity of novel triketone-containing quinoxaline as HPPD inhibitor.","date":"2021","source":"Pest management science","url":"https://pubmed.ncbi.nlm.nih.gov/34719096","citation_count":30,"is_preprint":false},{"pmid":"31537781","id":"PMC_31537781","title":"HPD degradation regulated by the TTC36-STK33-PELI1 signaling axis induces tyrosinemia and neurological damage.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31537781","citation_count":29,"is_preprint":false},{"pmid":"17640269","id":"PMC_17640269","title":"The tyrosine degradation gene hppD is transcriptionally activated by HpdA and repressed by HpdR in Streptomyces coelicolor, while hpdA is negatively autoregulated and repressed by HpdR.","date":"2007","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/17640269","citation_count":29,"is_preprint":false},{"pmid":"32756361","id":"PMC_32756361","title":"Based on the Virtual Screening of Multiple Pharmacophores, Docking and Molecular Dynamics Simulation Approaches toward the Discovery of Novel HPPD Inhibitors.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32756361","citation_count":25,"is_preprint":false},{"pmid":"7851880","id":"PMC_7851880","title":"Structure of the human 4-hydroxyphenylpyruvic acid dioxygenase gene (HPD).","date":"1994","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7851880","citation_count":23,"is_preprint":false},{"pmid":"7774914","id":"PMC_7774914","title":"A nonsense mutation in the 4-hydroxyphenylpyruvic acid dioxygenase gene (Hpd) causes skipping of the constitutive exon and hypertyrosinemia in mouse strain III.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7774914","citation_count":23,"is_preprint":false},{"pmid":"22866957","id":"PMC_22866957","title":"C4-alkoxy-HPD: a potent class of synthetic modulators surpassing nature in AI-2 quorum sensing.","date":"2012","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/22866957","citation_count":22,"is_preprint":false},{"pmid":"33222056","id":"PMC_33222056","title":"Effects of the novel HPPD-inhibitor herbicide QYM201 on enzyme activity and microorganisms, and its degradation in soil.","date":"2020","source":"Ecotoxicology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/33222056","citation_count":21,"is_preprint":false},{"pmid":"6221167","id":"PMC_6221167","title":"Cell biology of hematoporphyrin derivative (HPD).","date":"1983","source":"Lasers in surgery and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/6221167","citation_count":20,"is_preprint":false},{"pmid":"31780710","id":"PMC_31780710","title":"Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31780710","citation_count":19,"is_preprint":false},{"pmid":"31535847","id":"PMC_31535847","title":"Construction of Anti-hPD-L1 HCAb Nb6 and in Situ 124I Labeling for Noninvasive Detection of PD-L1 Expression in Human Bone Sarcoma.","date":"2019","source":"Bioconjugate chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31535847","citation_count":18,"is_preprint":false},{"pmid":"29894735","id":"PMC_29894735","title":"Characterization and safety evaluation of HPPD W336, a modified 4-hydroxyphenylpyruvate dioxygenase protein, and the impact of its expression on plant metabolism in herbicide-tolerant MST-FGØ72-2 soybean.","date":"2018","source":"Regulatory toxicology and pharmacology : RTP","url":"https://pubmed.ncbi.nlm.nih.gov/29894735","citation_count":18,"is_preprint":false},{"pmid":"35715048","id":"PMC_35715048","title":"Virtual screening based on pharmacophore model for developing novel HPPD inhibitors.","date":"2022","source":"Pesticide biochemistry and physiology","url":"https://pubmed.ncbi.nlm.nih.gov/35715048","citation_count":18,"is_preprint":false},{"pmid":"25884889","id":"PMC_25884889","title":"Rapamycin impairs HPD-induced beneficial effects on glucose homeostasis.","date":"2015","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25884889","citation_count":17,"is_preprint":false},{"pmid":"38340602","id":"PMC_38340602","title":"Physiological effects of maize stressed by HPPD inhibitor herbicides via multi-spectral technology and two-dimensional correlation spectrum technology.","date":"2024","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/38340602","citation_count":17,"is_preprint":false},{"pmid":"8394699","id":"PMC_8394699","title":"HPD-induced photodynamic changes in intracellular cyclic AMP levels in human bladder transitional carcinoma cells, clone T24.","date":"1993","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8394699","citation_count":17,"is_preprint":false},{"pmid":"33847923","id":"PMC_33847923","title":"Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).","date":"2021","source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/33847923","citation_count":16,"is_preprint":false},{"pmid":"37105629","id":"PMC_37105629","title":"Discovery of novel HPPD inhibitors: Virtual screening, molecular design, structure modification and biological evaluation.","date":"2023","source":"Pesticide biochemistry and physiology","url":"https://pubmed.ncbi.nlm.nih.gov/37105629","citation_count":16,"is_preprint":false},{"pmid":"37889480","id":"PMC_37889480","title":"First Report on Resistance to HPPD Herbicides Mediated by Nontarget-Site Mechanisms in the Grass Leptochloa chinensis.","date":"2023","source":"Journal of agricultural and food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37889480","citation_count":16,"is_preprint":false},{"pmid":"35259068","id":"PMC_35259068","title":"Vibrio splendidus virulence to Apostichopus japonicus is mediated by hppD through glutamate metabolism and flagellum assembly.","date":"2022","source":"Virulence","url":"https://pubmed.ncbi.nlm.nih.gov/35259068","citation_count":16,"is_preprint":false},{"pmid":"10984668","id":"PMC_10984668","title":"Gene mutation in hereditary progressive dystonia with marked diurnal fluctuation (HPD), strictly defined dopa-responsive dystonia.","date":"2000","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/10984668","citation_count":15,"is_preprint":false},{"pmid":"31060501","id":"PMC_31060501","title":"Using RNA-seq to characterize responses to 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor herbicide resistance in waterhemp (Amaranthus tuberculatus).","date":"2019","source":"BMC plant biology","url":"https://pubmed.ncbi.nlm.nih.gov/31060501","citation_count":13,"is_preprint":false},{"pmid":"35391497","id":"PMC_35391497","title":"Fluorescence kinetics study of twice laser irradiation based HpD-PDT for nonmelanoma skin cancer.","date":"2022","source":"Lasers in surgery and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35391497","citation_count":13,"is_preprint":false},{"pmid":"2942743","id":"PMC_2942743","title":"A study on the possible involvement of nonlinear mechanism of light absorption by HpD with Nd:YAG laser.","date":"1986","source":"Lasers in surgery and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/2942743","citation_count":13,"is_preprint":false},{"pmid":"32891822","id":"PMC_32891822","title":"Tyrosine metabolic enzyme HPD is decreased and predicts unfavorable outcomes in hepatocellular carcinoma.","date":"2020","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/32891822","citation_count":12,"is_preprint":false},{"pmid":"31926788","id":"PMC_31926788","title":"Evaluation of 64Cu radiolabeled anti-hPD-L1 Nb6 for positron emission tomography imaging in lung cancer tumor mice model.","date":"2019","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/31926788","citation_count":12,"is_preprint":false},{"pmid":"35848390","id":"PMC_35848390","title":"Computer-Assisted Proposition of Promising Aryloxyacetic Acid Derivatives as HPPD Inhibitors.","date":"2022","source":"Journal of agricultural and food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35848390","citation_count":11,"is_preprint":false},{"pmid":"33997102","id":"PMC_33997102","title":"Genetically blocking HPD via CRISPR-Cas9 protects against lethal liver injury in a pig model of tyrosinemia type I.","date":"2021","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/33997102","citation_count":11,"is_preprint":false},{"pmid":"3336250","id":"PMC_3336250","title":"Effects of photosensitizer (hematoporphyrin derivative-HPD) and light dose on vascular targets in the albino mouse ear.","date":"1988","source":"The Laryngoscope","url":"https://pubmed.ncbi.nlm.nih.gov/3336250","citation_count":11,"is_preprint":false},{"pmid":"6607227","id":"PMC_6607227","title":"In vitro hematoporphyrin (Hpd) inhibitory effects on some immunological assays.","date":"1983","source":"International journal of immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/6607227","citation_count":11,"is_preprint":false},{"pmid":"17388244","id":"PMC_17388244","title":"The sensitivity of the Bayesian HPD method to the choice of prior.","date":"2006","source":"Science & justice : journal of the Forensic Science Society","url":"https://pubmed.ncbi.nlm.nih.gov/17388244","citation_count":11,"is_preprint":false},{"pmid":"9325050","id":"PMC_9325050","title":"Human 4-hydroxyphenylpyruvate dioxygenase gene (HPD).","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9325050","citation_count":10,"is_preprint":false},{"pmid":"29438713","id":"PMC_29438713","title":"Synergistic tumoricidal effect of combined hPD-L1 vaccine and HER2 gene vaccine.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29438713","citation_count":10,"is_preprint":false},{"pmid":"31768442","id":"PMC_31768442","title":"Theoretical QSAR modelling and molecular docking studies of some 4-hydroxyphenylpyruvate dioxygenase (HPPD) enzyme inhibitors potentially used as herbicides.","date":"2019","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/31768442","citation_count":10,"is_preprint":false},{"pmid":"38408430","id":"PMC_38408430","title":"Integrated Virtual Screening and Validation toward Potential HPPD Inhibition Herbicide.","date":"2024","source":"Journal of agricultural and food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38408430","citation_count":9,"is_preprint":false},{"pmid":"38714361","id":"PMC_38714361","title":"Design, Synthesis, and Biological Activity of Novel Triketone-Containing Phenoxy Nicotinyl Inhibitors of HPPD.","date":"2024","source":"Journal of agricultural and food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38714361","citation_count":9,"is_preprint":false},{"pmid":"39748404","id":"PMC_39748404","title":"PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD).","date":"2025","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39748404","citation_count":8,"is_preprint":false},{"pmid":"38400685","id":"PMC_38400685","title":"Incidence of immunotherapy-related hyperprogressive disease (HPD) across HPD definitions and cancer types in observational studies: A systematic review and meta-analysis.","date":"2024","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38400685","citation_count":8,"is_preprint":false},{"pmid":"31054541","id":"PMC_31054541","title":"In-Silico analysis of missense SNPs in Human HPPD gene associated with Tyrosinemia type III and Hawkinsinuria.","date":"2019","source":"Computational biology and chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31054541","citation_count":8,"is_preprint":false},{"pmid":"37633023","id":"PMC_37633023","title":"Bach1 inhibitor HPP-D mediates γ-globin gene activation in sickle erythroid progenitors.","date":"2023","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/37633023","citation_count":7,"is_preprint":false},{"pmid":"1833890","id":"PMC_1833890","title":"[Uptake and distribution of hematoporphyrin derivatives (HPD) in arteriosclerotic and normal vessel segments].","date":"1991","source":"Zeitschrift fur Kardiologie","url":"https://pubmed.ncbi.nlm.nih.gov/1833890","citation_count":7,"is_preprint":false},{"pmid":"9210589","id":"PMC_9210589","title":"Sequence variation in the hpd gene of nonencapsulated Haemophilus influenzae isolated from patients with chronic bronchitis.","date":"1997","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/9210589","citation_count":7,"is_preprint":false},{"pmid":"20010535","id":"PMC_20010535","title":"Photo-oxidative action in cervix carcinoma cells induced by HPD - mediated photodynamic therapy.","date":"2009","source":"Experimental oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20010535","citation_count":7,"is_preprint":false},{"pmid":"33505377","id":"PMC_33505377","title":"Assessing the Effects of β-Triketone Herbicides on the Soil Bacterial and hppd Communities: A Lab-to-Field Experiment.","date":"2021","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/33505377","citation_count":6,"is_preprint":false},{"pmid":"31926848","id":"PMC_31926848","title":"Design of a degenerate primer pair to target a bacterial functional community: The hppd bacterial gene coding for the enzyme targeted by herbicides, a study case.","date":"2020","source":"Journal of microbiological methods","url":"https://pubmed.ncbi.nlm.nih.gov/31926848","citation_count":6,"is_preprint":false},{"pmid":"36800004","id":"PMC_36800004","title":"Species differences and human relevance of the toxicity of 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors and a new approach method in vitro for investigation.","date":"2023","source":"Archives of toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/36800004","citation_count":5,"is_preprint":false},{"pmid":"32109208","id":"PMC_32109208","title":"Variant analysis of HPD genes from two families showing elevated tyrosine upon newborn screening by tandem mass spectrometry (MS/MS).","date":"2020","source":"Journal of pediatric endocrinology & metabolism : JPEM","url":"https://pubmed.ncbi.nlm.nih.gov/32109208","citation_count":5,"is_preprint":false},{"pmid":"37064962","id":"PMC_37064962","title":"Therapeutic efficacy of plant-produced Nivolumab in transgenic C57BL/6-hPD-1 mouse implanted with MC38 colon cancer.","date":"2023","source":"Biotechnology reports (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/37064962","citation_count":5,"is_preprint":false},{"pmid":"40491422","id":"PMC_40491422","title":"HPD is an RNA-Binding Protein Sustaining Ovarian Cancer Cell Glycolysis, Tumor Growth, and Drug Resistance.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/40491422","citation_count":4,"is_preprint":false},{"pmid":"36470730","id":"PMC_36470730","title":"Pyomelanin production via heterologous expression of 4-hydroxyphenylpyruvate dioxygenase (HPPD) and construction of HPPD inhibitor screening model.","date":"2022","source":"Journal of bioscience and bioengineering","url":"https://pubmed.ncbi.nlm.nih.gov/36470730","citation_count":4,"is_preprint":false},{"pmid":"35715049","id":"PMC_35715049","title":"Identification and antioxidant capacity of 4-hydroxyphenylpyruvate dioxygenase (HPPD), a new favored herbicide target, in Apis cerana cerana.","date":"2022","source":"Pesticide biochemistry and physiology","url":"https://pubmed.ncbi.nlm.nih.gov/35715049","citation_count":4,"is_preprint":false},{"pmid":"36068455","id":"PMC_36068455","title":"Assessing the effects of β-triketone herbicides on HPPD from environmental bacteria using a combination of in silico and microbiological approaches.","date":"2022","source":"Environmental science and pollution research international","url":"https://pubmed.ncbi.nlm.nih.gov/36068455","citation_count":4,"is_preprint":false},{"pmid":"26464772","id":"PMC_26464772","title":"Molecular Cloning, Expression and Purification of Truncated hpd Fragment of Haemophilus influenzae in Escherichia coli.","date":"2015","source":"Jundishapur journal of microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/26464772","citation_count":4,"is_preprint":false},{"pmid":"8521727","id":"PMC_8521727","title":"Regional assignment of the human 4-hydroxyphenylpyruvate dioxygenase gene (HPD) to 12q24-->qter by fluorescence in situ hybridization.","date":"1995","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8521727","citation_count":4,"is_preprint":false},{"pmid":"39746561","id":"PMC_39746561","title":"Hematoporphyrin derivative-photodynamic therapy (HpD-PDT) for extensive vulvar and vaginal Bowen's disease: A case report.","date":"2024","source":"Photodiagnosis and photodynamic therapy","url":"https://pubmed.ncbi.nlm.nih.gov/39746561","citation_count":4,"is_preprint":false},{"pmid":"28766406","id":"PMC_28766406","title":"Molecular dynamics simulations of Hsp40 J-domain mutants identifies disruption of the critical HPD-motif as the key factor for impaired curing in vivo of the yeast prion [URE3].","date":"2017","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/28766406","citation_count":4,"is_preprint":false},{"pmid":"38927403","id":"PMC_38927403","title":"Molecular and Evolution In Silico Studies Unlock the h4-HPPD C-Terminal Tail Gating Mechanism.","date":"2024","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/38927403","citation_count":3,"is_preprint":false},{"pmid":"32690363","id":"PMC_32690363","title":"Development of a fluorescent probe for the detection of hPD-L1.","date":"2020","source":"Journal of bioscience and bioengineering","url":"https://pubmed.ncbi.nlm.nih.gov/32690363","citation_count":3,"is_preprint":false},{"pmid":"38537831","id":"PMC_38537831","title":"A commercial humic acid inhibits benzo(a)pyrene biodegradation by Paracoccus aminovorans HPD-2.","date":"2024","source":"The Science of the total environment","url":"https://pubmed.ncbi.nlm.nih.gov/38537831","citation_count":3,"is_preprint":false},{"pmid":"38869005","id":"PMC_38869005","title":"Data derived extrapolation factors (DDEFs) for rat to human interspecies extrapolation for the HPPD inhibitor mesotrione.","date":"2024","source":"Critical reviews in toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/38869005","citation_count":3,"is_preprint":false},{"pmid":"36951367","id":"PMC_36951367","title":"Study of two combined series of triketones with HPPD inhibitory activity by molecular modelling.","date":"2023","source":"SAR and QSAR in environmental research","url":"https://pubmed.ncbi.nlm.nih.gov/36951367","citation_count":3,"is_preprint":false},{"pmid":"40082037","id":"PMC_40082037","title":"Basing target enzyme study the enantioselective bioactivity action mechanism of flusulfinam, a novel HPPD inhibitor herbicide.","date":"2025","source":"Pesticide biochemistry and physiology","url":"https://pubmed.ncbi.nlm.nih.gov/40082037","citation_count":3,"is_preprint":false},{"pmid":"35761353","id":"PMC_35761353","title":"Leveraging structural and 2D-QSAR to investigate the role of functional group substitutions, conserved surface residues and desolvation in triggering the small molecule-induced dimerization of hPD-L1.","date":"2022","source":"BMC chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35761353","citation_count":3,"is_preprint":false},{"pmid":"37302640","id":"PMC_37302640","title":"Efficacy of hematoporphyrin injection (HpD) photodynamic therapy in the treatment of widespread extramammary Paget's disease.","date":"2023","source":"Photodiagnosis and photodynamic therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37302640","citation_count":3,"is_preprint":false},{"pmid":"21480481","id":"PMC_21480481","title":"HPPD: A newly recognized autosomal dominant disorder involving hypertelorism, preauricular sinus, punctal pits, and deafness mapping to chromosome 14q31.","date":"2011","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/21480481","citation_count":3,"is_preprint":false},{"pmid":"40899671","id":"PMC_40899671","title":"Curative Effect of Cutaneous Ulcer Wound Repair Through a Novel Liquid Dressing After HpD-PDT Treatment of Extramammary Paget's Disease-A Prospective, Semi-Lesion Controlled, Pilot Study.","date":"2025","source":"Journal of cosmetic dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/40899671","citation_count":3,"is_preprint":false},{"pmid":"9128393","id":"PMC_9128393","title":"[Segawa disease (hereditary progressive dystonia with marked diurnal fluctuation-HPD) and abnormalities in pteridin metabolism].","date":"1996","source":"Rinsho shinkeigaku = Clinical neurology","url":"https://pubmed.ncbi.nlm.nih.gov/9128393","citation_count":3,"is_preprint":false},{"pmid":"6241690","id":"PMC_6241690","title":"Cellular binding of hematoporphyrin derivative (HpD) in human bladder cancer cell line: KK-47.","date":"1984","source":"Progress in clinical and biological research","url":"https://pubmed.ncbi.nlm.nih.gov/6241690","citation_count":3,"is_preprint":false},{"pmid":"37914111","id":"PMC_37914111","title":"\"Structural responses of non-targeted bacterial and hppd communities to the herbicide tembotrione in soil\".","date":"2023","source":"The Science of the total environment","url":"https://pubmed.ncbi.nlm.nih.gov/37914111","citation_count":2,"is_preprint":false},{"pmid":"38679153","id":"PMC_38679153","title":"Sequence-dependent effects of hematoporphyrin derivatives (HPD) photodynamic therapy and cisplatin on lung adenocarcinoma cells.","date":"2024","source":"Photodiagnosis and photodynamic therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38679153","citation_count":2,"is_preprint":false},{"pmid":"40017298","id":"PMC_40017298","title":"Computer-Aided Design and Pharmacophore-Based Screening of a Diverse Combinatorial Library of Phytoselective Aryloxyacetic Acid Derivatives as HPPD Inhibitors.","date":"2025","source":"Journal of agricultural and food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40017298","citation_count":2,"is_preprint":false},{"pmid":"1391432","id":"PMC_1391432","title":"Biological effects of photoactivated-HPD and cholesteryl hemisuccinate on erythroid differentiation.","date":"1992","source":"Biomaterials, artificial cells, and immobilization biotechnology : official journal of the International Society for Artificial Cells and Immobilization Biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/1391432","citation_count":2,"is_preprint":false},{"pmid":"37215717","id":"PMC_37215717","title":"Case report: A combined immunotherapy strategy as a promising therapy for MSI-H colorectal carcinomas with multiple HPD risk factors.","date":"2023","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37215717","citation_count":2,"is_preprint":false},{"pmid":"8965384","id":"PMC_8965384","title":"[Molecular genetics of hereditary progressive dystonia (HPD/Segawa's disease)].","date":"1996","source":"Nihon rinsho. Japanese journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8965384","citation_count":2,"is_preprint":false},{"pmid":"6520474","id":"PMC_6520474","title":"[Experimental studies on photoradiation therapy by hematoporphyrin derivative (HpD) and argon dye laser].","date":"1984","source":"Nihon Sanka Fujinka Gakkai zasshi","url":"https://pubmed.ncbi.nlm.nih.gov/6520474","citation_count":2,"is_preprint":false},{"pmid":"1368556","id":"PMC_1368556","title":"A practical test for in vitro evaluation of photosensitization: assessment with hematoporphyrin derivative (HPD).","date":"1990","source":"Cytotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/1368556","citation_count":2,"is_preprint":false},{"pmid":"6241694","id":"PMC_6241694","title":"Fluorescing cells in sputum after parenteral HpD.","date":"1984","source":"Progress in clinical and biological research","url":"https://pubmed.ncbi.nlm.nih.gov/6241694","citation_count":2,"is_preprint":false},{"pmid":"1327693","id":"PMC_1327693","title":"[Effect of combined use of chemotherapeutic agents and hematopor--phyrin derivative (HPD) on human gastric cancer cell line in vitro].","date":"1992","source":"Zhonghua zhong liu za zhi [Chinese journal of oncology]","url":"https://pubmed.ncbi.nlm.nih.gov/1327693","citation_count":2,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49371,"output_tokens":2644,"usd":0.093886,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10007,"output_tokens":3283,"usd":0.066055,"stage2_stop_reason":"end_turn"},"total_usd":0.159941,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2019,\n      \"finding\": \"HPD protein stability is regulated by a TTC36-STK33-PELI1 signaling axis: TTC36 binds HPD and blocks STK33 from phosphorylating HPD at T382; T382 phosphorylation recruits the FHA-domain E3 ligase PELI1, which polyubiquitylates HPD and targets it for proteasomal degradation. TTC36 deficiency in mice reduces hepatic HPD, causing tyrosinemia and hippocampal neuronal damage.\",\n      \"method\": \"Co-immunoprecipitation, phosphorylation assays, ubiquitylation assays, Ttc36-knockout mouse model with biochemical and behavioral phenotyping\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP plus phosphorylation/ubiquitylation assays plus in vivo KO mouse phenotype, multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"31537781\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Loss of HPD enzymatic activity in liver cells reduces ketone body production, which activates the AMPK/mTOR/p70S6K pathway and mTOR-dependent glutaminase (GLS) activation, shifting cellular metabolism toward glutamine anaplerosis and TCA cycle replenishment, thereby promoting tumorigenic and proliferative phenotypes.\",\n      \"method\": \"HPD silencing (siRNA/shRNA) in liver cancer cell lines, metabolomics profiling, isotope tracing (13C-glutamine), AMPK/mTOR pathway inhibitor experiments\",\n      \"journal\": \"Cell Reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — isotope tracing plus metabolomics plus pathway inhibitor epistasis in a single study with multiple orthogonal methods\",\n      \"pmids\": [\"34433044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Beyond its canonical enzymatic role, HPD functions as an RNA-binding protein (RBP) that binds the RRACH motif of target mRNAs through two dsRNA-binding domains (RBDs), enhancing global mRNA translation. Specifically, HPD binding promotes translation of glycolytic enzyme mRNAs TPI and ENO1, driving glycolysis, tumor growth, and drug resistance in ovarian cancer cells.\",\n      \"method\": \"RNA-binding protein assays, identification of RBDs by domain mapping, mRNA translation assays, glycolysis flux measurements, RBD-domain disruption experiments, tumor growth and drug response assays\",\n      \"journal\": \"Advanced Science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct RNA-binding and functional translation assays, single lab, multiple orthogonal methods; preprint/recent publication, not yet independently replicated\",\n      \"pmids\": [\"40491422\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"HPD (4-hydroxyphenylpyruvate dioxygenase) catalyzes the second step in tyrosine catabolism; genetic deficiency (loss-of-function mutations including missense and nonsense mutations) causes accumulation of tyrosine and phenolic metabolites, resulting in tyrosinemia type III with neurological symptoms.\",\n      \"method\": \"Mutation identification in HPD gene by sequencing in patients with biochemically confirmed enzyme deficiency; genotype-phenotype correlation\",\n      \"journal\": \"Human Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — sequencing-based mutation identification in multiple unrelated families with confirmed enzyme deficiency; establishes catalytic function by loss-of-function but no in vitro reconstitution\",\n      \"pmids\": [\"10942115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"A nonsense mutation in exon 7 of the mouse Hpd gene causes partial exon skipping, generating a truncated non-functional enzyme, leading to reduced 4-hydroxyphenylpyruvate dioxygenase activity and hypertyrosinemia in mouse strain III; this strain is a model for human tyrosinemia type 3.\",\n      \"method\": \"Genomic sequencing, RT-PCR to detect exon skipping, enzymatic activity assays in liver tissue\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — combined sequencing, mRNA analysis, and enzymatic activity measurement; single study but multiple orthogonal methods\",\n      \"pmids\": [\"7774914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"In Fah-/- Hpd-/- double-mutant mice, the absence of HPD activity prevents accumulation of homogentisate-derived toxic metabolites (including succinylacetone) and protects against liver and renal disease. When homogentisate is exogenously administered to Fah-/- Hpd-/- mice, rapid apoptosis of proximal renal tubular cells occurs via caspase-dependent mechanisms, and renal Fanconi syndrome develops; apoptosis was blocked by caspase inhibitor YVAD but renal dysfunction was not, indicating these operate through separate pathways.\",\n      \"method\": \"Double-mutant mouse model (Fah-/- Hpd-/-), homogentisate administration, caspase inhibitor pretreatment (YVAD), urine metabolite analysis, histopathology\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic double-KO model with pharmacological intervention (caspase inhibitor), in vivo metabolite tracing, and histopathology; multiple orthogonal methods establishing pathway position\",\n      \"pmids\": [\"10665936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The human HPD gene is over 30 kb long, split into 14 exons, and expressed predominantly in liver. Analysis of the 5' flanking region identified hepatocyte-specific and liver-enriched transcription factor binding sites consistent with regulated hepatic expression.\",\n      \"method\": \"Genomic library screening, restriction mapping, exon-boundary sequencing, Northern blot analysis of tissue expression, 5'-flanking sequence analysis\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — genomic structure determination with Northern blot confirmation of liver-specific expression; single study but direct experimental characterization of gene structure and expression\",\n      \"pmids\": [\"7851880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The human HPD gene spans ~21 kb with 14 exons and 13 introns; the transcription start site is 35 nt upstream of the translational start. The 5'-flanking region contains CRE, AP-2, and Sp1 regulatory elements; transient transfection with CAT reporter constructs indicated that cAMP may regulate HPD transcription. Highest expression is in liver by Northern blot.\",\n      \"method\": \"Genomic library screening, PCR, DNA sequencing, Northern blot, transient transfection with CAT reporter constructs\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct characterization of promoter elements with functional reporter assay; single lab, liver-specific expression confirmed by Northern blot\",\n      \"pmids\": [\"9325050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CRISPR-Cas9-mediated biallelic disruption of HPD in FAH-deficient pigs redirects tyrosine catabolism upstream of the pathogenic pathway, protecting against fumarylacetoacetate hydrolase deficiency-induced lethal liver injury; HPD ablation also ameliorated oxidative stress, inflammatory responses, and restored liver metabolic gene expression profiles.\",\n      \"method\": \"CRISPR-Cas9 cytoplasmic microinjection in FAH-mutant pig embryos, F1 generation characterization, liver histopathology, gene expression profiling, oxidative stress assays\",\n      \"journal\": \"Molecular Therapy: Methods & Clinical Development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — large-animal genetic epistasis model demonstrating HPD's pathway position upstream of pathogenic metabolites; single study with multiple phenotypic readouts\",\n      \"pmids\": [\"33997102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Computational modeling and in silico evolutionary analysis of human 4-HPPD revealed that the C-terminal tail acts as a gating mechanism for the active site, with two novel residues identified as key regulators of C-terminal tail conformational change; a full-length 3D structural model of human 4-HPPD was proposed.\",\n      \"method\": \"Bioinformatics/molecular dynamics simulations, evolutionary analysis, homology modeling; no experimental in vitro or structural validation\",\n      \"journal\": \"Biomedicines\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — computational prediction only; no experimental structural or functional validation reported in the abstract\",\n      \"pmids\": [\"38927403\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HPD (4-hydroxyphenylpyruvate dioxygenase) catalyzes the second step of tyrosine catabolism (conversion of 4-hydroxyphenylpyruvate to homogentisate) primarily in liver; its stability is regulated by the TTC36-STK33-PELI1 axis (TTC36 blocks STK33-mediated T382 phosphorylation that otherwise recruits PELI1 for polyubiquitylation and degradation); loss of HPD reduces ketone bodies, activating mTOR/GLS-dependent glutamine anaplerosis; and unexpectedly HPD also functions as an RNA-binding protein that promotes translation of glycolytic enzyme mRNAs (TPI, ENO1) through dsRNA-binding domains.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"HPD (4-hydroxyphenylpyruvate dioxygenase) catalyzes the second step of tyrosine catabolism, converting 4-hydroxyphenylpyruvate to homogentisate, and is expressed predominantly in liver under hepatocyte-specific transcriptional control [#3, #6]. Loss-of-function mutations abolish this activity and cause accumulation of tyrosine and phenolic metabolites, producing tyrosinemia type III with neurological features in humans and a parallel hypertyrosinemia phenotype in mouse [#3, #4]. Because HPD acts upstream of the toxic homogentisate-derived metabolites (including succinylacetone) generated in fumarylacetoacetate hydrolase deficiency, genetic ablation of HPD in Fah-deficient mice and pigs redirects flux away from the pathogenic branch and protects against lethal liver and renal injury; exogenous homogentisate restores caspase-dependent apoptosis of proximal renal tubular cells, placing HPD precisely at this metabolic branch point [#5, #8]. HPD protein abundance is set post-translationally by a TTC36-STK33-PELI1 axis: STK33 phosphorylates HPD at T382 to recruit the FHA-domain E3 ligase PELI1 for polyubiquitylation and proteasomal degradation, while TTC36 binding blocks this phosphorylation, and TTC36 loss in mice depletes hepatic HPD, causing tyrosinemia and hippocampal damage [#0]. Beyond catabolism, loss of HPD enzymatic activity lowers ketone body production and activates AMPK/mTOR/p70S6K signaling and mTOR-dependent glutaminase to drive glutamine anaplerosis and proliferative phenotypes [#1]. HPD additionally moonlights as an RNA-binding protein that recognizes the RRACH motif through two dsRNA-binding domains and enhances translation of glycolytic enzyme mRNAs TPI and ENO1, promoting glycolysis, tumor growth, and drug resistance [#2].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Establishing where HPD is expressed and how it is transcriptionally controlled was needed to anchor its physiological role; defining the gene's structure and liver-enriched expression located its function in hepatic tyrosine metabolism.\",\n      \"evidence\": \"Genomic library screening, exon-boundary sequencing, Northern blot tissue profiling, and 5'-flanking analysis\",\n      \"pmids\": [\"7851880\", \"9325050\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Promoter element function tested only by reporter assay, not in vivo\", \"Does not address extra-hepatic expression or non-catalytic functions\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"A causal link between Hpd disruption and disease was established in vivo when a nonsense mutation causing exon skipping produced a truncated enzyme and hypertyrosinemia, defining a tyrosinemia type III model.\",\n      \"evidence\": \"Genomic sequencing, RT-PCR exon-skipping analysis, and liver enzymatic activity assays in mouse strain III\",\n      \"pmids\": [\"7774914\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vitro reconstitution of the truncated enzyme\", \"Mechanism of neurological consequences not addressed\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Whether human HPD mutations are disease-causing was confirmed by identifying loss-of-function mutations in patients with biochemically confirmed enzyme deficiency, defining HPD as the catalytic basis of tyrosinemia type III.\",\n      \"evidence\": \"Mutation sequencing and genotype-phenotype correlation in unrelated families with confirmed enzyme deficiency\",\n      \"pmids\": [\"10942115\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vitro enzymatic reconstitution of mutant proteins\", \"Structure-function basis of individual mutations not resolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"The precise pathway position of HPD relative to downstream toxic metabolites was resolved using a Fah/Hpd double-knockout, showing HPD acts upstream of homogentisate-derived succinylacetone and that its ablation is protective.\",\n      \"evidence\": \"Fah-/- Hpd-/- mouse model, exogenous homogentisate administration, caspase-inhibitor (YVAD) intervention, urine metabolite analysis, and histopathology\",\n      \"pmids\": [\"10665936\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking homogentisate to caspase-independent renal dysfunction unresolved\", \"Does not address HPD regulation\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"How HPD protein levels are controlled post-translationally was unknown; the TTC36-STK33-PELI1 axis was defined as a phosphorylation- and ubiquitylation-dependent stability switch governing hepatic HPD abundance.\",\n      \"evidence\": \"Reciprocal Co-IP, T382 phosphorylation and ubiquitylation assays, and a Ttc36-knockout mouse with biochemical and behavioral phenotyping\",\n      \"pmids\": [\"31537781\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stimuli that engage STK33-mediated HPD phosphorylation not defined\", \"Whether this axis operates outside liver unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The metabolic consequences of losing HPD enzymatic activity were defined: reduced ketone bodies activate AMPK/mTOR signaling and glutaminase-driven glutamine anaplerosis, reprogramming metabolism toward proliferation.\",\n      \"evidence\": \"HPD silencing in liver cancer cells, metabolomics, 13C-glutamine isotope tracing, and AMPK/mTOR inhibitor epistasis\",\n      \"pmids\": [\"34433044\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this signaling cascade operates in normal hepatocytes vs cancer cells unclear\", \"Direct sensor linking ketone levels to AMPK not identified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"HPD's epistatic position was confirmed in a large-animal model when biallelic CRISPR disruption in FAH-deficient pigs rerouted tyrosine catabolism upstream of pathogenic metabolites and protected against lethal liver injury.\",\n      \"evidence\": \"CRISPR-Cas9 embryo microinjection in FAH-mutant pigs, liver histopathology, expression profiling, and oxidative stress assays\",\n      \"pmids\": [\"33997102\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Long-term metabolic consequences of HPD ablation in pigs not assessed\", \"Single study\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A non-catalytic moonlighting function was uncovered: HPD binds RRACH-motif mRNAs through two dsRNA-binding domains and enhances translation of glycolytic enzyme transcripts TPI and ENO1, linking it to glycolysis and tumor phenotypes.\",\n      \"evidence\": \"RNA-binding assays, domain mapping of RBDs, translation and glycolysis flux measurements, and RBD-disruption tumor/drug-response experiments\",\n      \"pmids\": [\"40491422\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, not independently replicated\", \"Relationship between RNA-binding and catalytic functions of HPD undefined\", \"Structural basis of RRACH recognition unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A structural rationale for HPD active-site regulation was proposed in silico, identifying a C-terminal gating tail and key residues governing its conformational change.\",\n      \"evidence\": \"Molecular dynamics simulations, evolutionary analysis, and homology modeling without experimental validation\",\n      \"pmids\": [\"38927403\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Purely computational; no experimental structural or functional validation\", \"Predicted gating residues not tested by mutagenesis\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How HPD's enzymatic, stability-control, and RNA-binding functions are integrated within a single protein and coordinated across tissues remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No experimental structure of full-length human HPD or its RNA-bound state\", \"Unknown whether RNA-binding competes with or is independent of catalysis\", \"Physiological triggers of the TTC36-STK33-PELI1 axis undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [3, 4, 5]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"localization\": [],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 5]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TTC36\", \"STK33\", \"PELI1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":6,"faith_total":6,"faith_pct":100.0}}